2012-08-18 19:48:01 - Fast Market Research recommends "CNS Lymphoma - Pipeline Review, H2 2012" from Global Markets Direct, now available

Global Markets Direct's, 'CNS Lymphoma - Pipeline Review, H2 2012', provides an overview of the CNS Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for CNS Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for CNS Lymphoma. 'CNS Lymphoma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/449602_cns_lymphoma_pipeline_review_h2_2012. ..


Note*: Certain sections in the report may be removed or altered based on the availability

and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for CNS Lymphoma.
* A review of the CNS Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the CNS Lymphoma pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for CNS Lymphoma.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding CNS Lymphoma pipeline depth and focus of CNS Lymphoma therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

CNS Lymphoma Therapeutic Products under Development, Key Players in CNS Lymphoma Therapeutics, CNS Lymphoma Pipeline Overview, CNS Lymphoma Pipeline, CNS Lymphoma Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
CNS Lymphoma Overview
Therapeutics Development
An Overview of Pipeline Products for CNS Lymphoma
CNS Lymphoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
CNS Lymphoma Therapeutics - Products under Investigation by Universities/Institutes
CNS Lymphoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Alimta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alimta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Rituximab + Methotrexate + Leucovorin + Temozolomide + Cytarabine + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine + Methotrexate + Thiotepa + Sargramostim + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methotrexate + Leucovorin + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Idarubicin + Methotrexate + Filgrastim + Ara-C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
procarbazine + lomustine + vincristine + radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HAART + Methotrexate + Rituximab + Leucovorin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Methotrexate + Teniposide + BCNU + Prednisolone + ARA-C + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CNS Lymphoma Therapeutics - Discontinued Products
CNS Lymphoma Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for CNS Lymphoma, H2 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=449602&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.